Escitalopram
Product Images NDC 68258-7128

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Escitalopram (NDC 68258-7128). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-7128-xx (Ndc 68258 7128 Xx West Ward)

Label for Escitalopram 10 mg tablets by Dispensing Solutions, Inc. The label shows the product name, strength, dosage form as tablets, and notes it is prescription only. The NDC 68258-7128-XX and product ID 7128-X are visible. It includes manufacturer and bulk source information, storage instructions, and warnings. The label design includes barcodes and the Dispensing Solutions logo.*

FDA Label Image

Table 1 (Escitalopram 1)

A table titled 'Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated' showing age ranges with corresponding increases or decreases in suicidality cases compared to placebo. It presents additional cases for ages under 18 and 18-24 and fewer cases for ages 25-64 and 65 and older.*

FDA Label Image

Table 2 (Escitalopram 2)

A data table summarizing treatment-emergent adverse reactions with a frequency of 2% or more in patients treated with escitalopram oxalate compared to placebo for major depressive disorder. It includes categories such as autonomic nervous system disorders, central and peripheral nervous system disorders, gastrointestinal disorders, psychiatric disorders, respiratory system disorders, and urogenital issues, with corresponding percentages for escitalopram (N=715) and placebo (N=592).*

FDA Label Image

Table 3 (Escitalopram 3)

A table presenting treatment-emergent adverse reactions observed with Escitalopram oxalate compared to placebo in patients with generalized anxiety disorder. The table categorizes adverse reactions by system (e.g., autonomic nervous, gastrointestinal, psychiatric) and lists the percentage of patients experiencing each reaction for Escitalopram oxalate (N=429) and placebo (N=427), highlighting events occurring at 2% or greater frequency than placebo.*

FDA Label Image

Table 4 (Escitalopram 4)

A data table titled 'Incidence of Common Adverse Reactions in Patients with Major Depressive Disorder' comparing adverse reactions for Placebo, 10 mg/day Escitalopram oxalate, and 20 mg/day Escitalopram oxalate in patient groups (N=311, N=310, N=125 respectively). The table lists percentages for reactions including insomnia, diarrhea, dry mouth, somnolence, dizziness, increased sweating, constipation, fatigue, and indigestion.*

FDA Label Image

Table 5 (Escitalopram 5)

Table comparing the incidence of sexual side effects in placebo-controlled clinical trials for Escitalopram oxalate versus placebo. It presents percentages of adverse events including ejaculation disorder, decreased libido, and impotence in males, as well as decreased libido and anorgasmia in females.*

FDA Label Image

Esc Chem Structure (Escitalopram 6)

Chemical structure diagram of escitalopram oxalate, showing the molecular formula C20H21FN2O.C2H2O4 and a molecular weight of 414.40, as labeled in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.